

1382. Acid-Fast Bacilli Testing Trends at 43 In- and Outpatient Facilities and Nontuberculous Mycobacterial Pulmonary Isolation Rate, United States, 2009–2015

Yi Ling Lai, MPH¹; Emily Ricotta, PhD, ScM¹; Kenneth Olivier, MD, MPH; Sameer S. Kadri, MD, MS²; D. Rebecca Prevots, PhD¹; ¹National Institutes of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland; ²National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; ³NIH Clinical Center, Bethesda, Maryland

Session: 153. Mycobacteria
Friday, October 4, 2019: 12:15 PM



Background. The prevalence of nontuberculous mycobacterial pulmonary disease (NTM PD) is increasing in the United States and globally. The reasons for this increase are not clear but could be related to both gained awareness leading to increased mycobacterial testing, or to a true NTM PD increase. To further examine the role of testing rates in the observed increase, we studied trends in Acid-Fast Bacteria (AFB) testing and NTM isolation positivity using a large Electronic Health Record (EHR) dataset in the United States.

Methods. Using the Cerner *Health Facts* EHR dataset, we extracted microbiologic, demographic, and clinical data for patient encounters (inpatient or outpatient), with ≥ 1 orders for AFB respiratory cultures. The analysis was limited to the 43 facilities reporting continuously for the period 2009–2015. A patient with at least one AFB test was considered tested (AFB) and a patient with at least one pathogenic NTM respiratory isolate was considered positive. Trends in AFB testing and NTM positivity were estimated using log-linked Poisson regression ($P < 0.05$).

Results. From 2009 through 2015, of 14.8 million patients, 65,010 had 142,315 AFB tests, averaging 2.2 AFB tests/patient, for an overall testing prevalence of 0.43%; the annual testing prevalence remained unchanged during the study period ($P = 0.44$) (Figure 1). Of the 65,010 patients with AFB tests, 3,942 (6.1%) had ≥ 1 pathogenic NTM species, for an overall pulmonary NTM isolation prevalence of 2.7/10,000 patients represented in Cerner *Health Facts* dataset. Of the patients that had at least one pathogenic NTM, 3,094 (78%) had *M. avium* complex, and 265 (7%) had *M. abscessus/chelonae*, (Figure 2). Among patients with at least 1 NTM-positive culture, 138 patients had concomitant growth of *M. tuberculosis*.

Conclusion. Increases in NTM PD are not explained by increases in AFB testing, which remained constant in the population represented here.

This study was funded in part by the Division of Intramural Research, NIAID, NIH.



Disclosures. All authors: No reported disclosures.

1383. Everolimus is Associated with an Increased Risk of Tuberculosis in Solid-Organ Transplant Recipients

Hsin-Yun Sun, MD¹; Aristine Cheng, MBBSChir¹; So-Meng Wang, MD²;

Meng-Kun Tsai, MD¹; Yih-Shang Chen, Surgery¹; Sheoi-Shen Wang, Surgery¹; Cheng-Maw Ho, MD¹; Rey-Heng Hu, MD¹; Hsao-Hsun Hsu, MD³; Chi-Tai Fang, MD PhD³; Yee-Chun Chen, MD, PhD¹; Shan-Chwen Chang, MD, PhD¹; ¹National Taiwan University Hospital, Taipei, Taiwan (Republic of China); ²Fu Jen Catholic University Hospital, New Taipei City, New Taipei, Taiwan (Republic of China); ³National Taiwan University, Taipei, Taiwan (Republic of China)

Session: 153. Mycobacteria
Friday, October 4, 2019: 12:15 PM

Background. Tuberculosis (TB) is an important post-transplant infection. Everolimus has been documented to reduce the risk of cytomegalovirus infection in transplant recipients, but its impact on other infections is less known. The present study aimed to assess immunosuppressive regimens on TB risk in solid-organ transplant (SOT) recipients via a matched case-control study.

Methods. From May 2005 to December 2018, SOT recipients with TB were retrospectively identified, and those without TB undergoing transplantation at the same university hospital were selected as controls. Controls and cases were matched by age (± 5 years), transplant type and year (± 5 years) at a ratio of 4:1. Conditional logistic regression was used to analyze the risk factors of TB.

Results. TB developed in 30 SOT recipients (13 kidney, 7 heart, 6 liver, and 4 lung) after a mean duration of 1,601 days after transplantation, with predominant lung involvement (87%). The diagnosis was made by culture in 70% and pathology in 17%. Rifamycins-based regimens were used in 27 cases, and 4 developed rejection without graft failure. A total of 106 controls were selected. At the time of TB diagnosis, cases were more likely to use everolimus than controls (27% vs. 11%, $P < 0.05$), but no significant differences were observed in the use of tacrolimus, cyclosporin, sirolimus, prednisolone, or mycophenolate mofetil. The median duration of everolimus use was 585 and 698 days in 8 cases and 12 controls, respectively. Multivariable analysis showed that everolimus use (adjusted odds ratio [aOR] 22.3, 95% confidence interval [CI] 2.5–203.0) and hemodialysis (aOR 19.6, 95% CI 1.3–287.1) were independently associated with TB.

Conclusion. TB is more likely to develop in SOT recipients on everolimus and hemodialysis. Further studies to confirm our findings are warranted, and TB risk assessment should be performed for those receiving everolimus and hemodialysis.

Disclosures. All authors: No reported disclosures.

1384. Mycobacterium marinum Infection: 21 Years of Experience at a Tertiary-Care Hospital

Natalia E. Castillo Almeida, MD¹; Pooja Gurram, MBBS¹; Omar Abu Saleh, MBBS²; ¹Mayo Clinic, Rochester, Minnesota; ²Mayo Clinic, Rochester, Minnesota

Session: 153. Mycobacteria
Friday, October 4, 2019: 12:15 PM

Background. *Mycobacterium marinum* is a slow-growing, non-tuberculous mycobacterium responsible for skin and soft-tissue infections (SSTIs), tenosynovitis, and osteomyelitis (OM). We conducted a retrospective study describing the risk, clinical course, and outcome of *M. marinum* infection.

Methods. Adult patients with culture-confirmed *M. marinum* infections were identified from the mycology laboratory at Mayo Clinic, Rochester from January 1998 to December 2018. *M. marinum* infection was defined as uncomplicated (limited to SST) and complicated (tenosynovitis, OM, or disseminated).

Results. Forty-six cases of culture-confirmed infection with *M. marinum* were included (Table 1). Only 16 cases (35%) reported a water exposure and 22 (48%) involved finger and/or hand trauma. The median time to diagnosis was 3.6 months. Most patients (76%) presented with uncomplicated *M. marinum* infection with skin lesions mainly localized in the upper limb (Table 2). QuantiFERON and PPD were positive in 4 (8%) and 2 (4%) cases, respectively. Granulomatous inflammation and positive special stains were noted in 34 (74%) and 11 (24%) cases, respectively. Cases with complicated *M. marinum* infection had a longer duration of symptoms and length of treatment ($P < 0.05$) (Table 3). Prior to diagnosis, 63% of patients received at least one antibiotic for bacterial SSTIs. More than 50% of the patients diagnosed with *M. marinum* received a one drug regimen and 8% did not initiate therapy. Median treatment duration was 4.4 months. Twenty-six cases (56%) had susceptibilities performed and treatment modifications were made in 10 cases (38%). From the patients that started therapy, 73% completed therapy and 33% were lost to follow up. Cured was achieved in 87% of cases that completed therapy, 2 cases (6%) had a recurrence, and only one patient with active malignancy had a positive blood culture and died. Twelve (44%) and 10 cases (37%) were cured with one and two-drug regimens, respectively.

Conclusion. Most patients with *M. marinum* infection present as an uncomplicated infection in the upper limb. Classical exposure was only suspected in a third of the cases. Patients with complicated *M. marinum* infection had a prolonged duration of symptoms and lengthy treatment. Most patients were successfully treated with a one and two-drug regimen.

Table 1. Baseline characteristics

	N = 46
Male (%)	28 (60.9)
Age, median (range)	59 (19-86)
Immunosuppression (%)	8 (17.4)
Comorbidities	
Diabetes (%)	5 (11)
Chronic kidney disease (%)	2 (4.4)
Autoimmune disorder * (%)	5 (11)
Active malignancy (%)	1 (2.2)

*Autoimmune disorder: Crohn's disease, DM type 1, Rheumatoid arthritis, Ulcerative Colitis and Polymyalgia rheumatica.